Therefore, LTA4H inhibitors, 5-Lipoxygenase Activating Protein inhibitors and Leukotriene-B4 receptor antagonists might represent a potential therapeutic strategy that could modulate key aspects of early-onset asthma [40, 54]. The gene discussed is LTB4R; the disease is asthma.